CUA Educational Content

Treatment of non-metastatic CRPC: THE AR-TARGETED THERAPIES

A CLINICAL SUPPORT TOOL:

Three androgen-receptor (AR)-targeted therapies have been approved in Canada for the treatment of non-metastatic castrate-resistant prostate cancer (nmCRPC) – apalutamide, darolutamide, and enzalutamide.

DEVELOPED BY: Ricardo Rendon & Troy Sitland

image speakers

 

 

 


This tool has been developed through an unrestricted educational grant from Bayer Inc.